Physician profile
Devjit S Nayar
NPI 1093787806
$257,731.13
in general payments reported to CMS, 2019-2025
33 companies · $17K in 2025
The $17K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $13K · 2021: $21K · 2022: $35K · 2023: $30K · 2024: $94K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $105K · Travel and Lodging: $24K · Food and Beverage: $9,033 · Consulting Fee: $1,800 · Education: $96.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $105,187.50 |
| Travel and Lodging | $23,862.38 |
| Food and Beverage | $9,032.94 |
| Consulting Fee | $1,800.00 |
| Education | $96.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $92,600.19 | 2024-2025 | Voquezna |
| Abbvie INC. | $81,864.60 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $24,961.47 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23,684.57 | 2019-2025 | Trulance, Xifaxan |
| Conmed Corporation | $12,991.80 | 2019 | |
| Allergan, INC. | $9,322.53 | 2019-2020 | |
| Gilead Sciences, INC. | $4,701.71 | 2019-2025 | |
| Celgene Corporation | $3,758.76 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $567.31 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $550.07 | 2019-2025 | Entyvio |
| Ironwood Pharmaceuticals, INC | $521.05 | 2019-2024 | Linzess |
| Ardelyx, INC. | $369.42 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $367.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $356.07 | 2019-2025 | |
| Braintree Laboratories, INC. | $147.10 | 2019-2024 | Suflave, Sutab |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $144.95 | 2020-2022 | |
| Medtronic, INC. | $138.10 | 2023 | Interstim |
| Merck Sharp & Dohme LLC | $82.51 | 2019-2021 | |
| Novo Nordisk INC | $77.04 | 2025 | Wegovy |
| Qol Medical, LLC | $71.94 | 2019-2023 | Sucraid |
| Intercept Pharmaceuticals, INC. | $71.07 | 2019-2022 | |
| Lilly USA, LLC | $70.68 | 2023-2025 | Omvoh |
| Cumberland Pharmaceuticals, INC. | $54.00 | 2019-2020 | |
| Celltrion USA INC. | $50.82 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $45.00 | 2022-2023 | Aemcolo, Movantik, Talicia |
| Concordia Pharmaceuticals INC. | $39.56 | 2019 | |
| Daiichi Sankyo INC. | $31.13 | 2021 | |
| Boston Scientific Corporation | $20.01 | 2020 | |
| Aimmune Therapeutics, INC. | $18.24 | 2025 | Vowst |
| Shionogi INC | $13.58 | 2019 | |
| Alfasigma USA, INC. | $13.38 | 2020 | |
| Ethicon US, LLC | $13.07 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devjit Nayar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.